Colorectal cancer has an important place in worldwide death from cancer causes. Angiogenesis, in which angiogenic factors such as VEGF and basic FGF have a key role, is an important factor in patient survival with respect to progression and metastatic spreading in colorectal cancer. In this study, we aimed to determine whether serum VEGF and bFGF pre-and post-treatment serum levels are decisive in evaluating response to treatment and progression in metastatic colorectal cancer (mCRC) patients treated with FOLFIRI-bevacizumab.
INTRODUCTION
Colorectal cancer (CRC) is the fourth most common cancer in men and women (1) . CRC represents a major public health issue due to its high prevalence and mortality rate. 2, 3 Angiogenesis is essential for cancer growth and metastasis. VEGF is a key modulator of angiogenesis, and its over expression is correlated with advanced disease and poor prognosis. 4 Bevacizumab, a recombinant humanized anti-VEGF mAb, is the most advanced anti-angiogenic agent clinically. 5 The integration of bevacizumab in the management of CRC has provided major improvements for patients with metastatic CRC disease. 6 Investigations are currently underway to determine genetic profiles or other patient characteristics that may be of use in identifying patients who will benefit from targeted agents and how best to combine those agents with the standard cytotoxic regimens . 1 It has been reported that the establishment of VEGF and bFGF levels in circulation may provide information on the tumor vascularity and the response to antiangiogenic therapy. 7 We aimed to determine whether the surveillance of serum VEGF and bFGF levels can be beneficial in terms of evaluating the therapy response and survival of mCRC patients treated with FOLFIRI-bevacizumab.
PATIENTS AND METHODS
Between September 2006 and May 2008, 33 patients histologically diagnosed with metastatic colon or rectum cancer to receive first-line treatment were established to be eligible for the study. The median age (range) was 61 (38-75) years. Healthy control group was 59 (41-71)years. After obtaining informed consent the patients were involved in the study and the local Ethical, Committee approved the study. Blood samples for serum levels VEGF and bFGF were collected at baseline and on Day 1 of chemotherapy cycles 4, 8, and 12 at the Medical Oncology Department of Eskisehir Osmangazi University. Patients were evaluated according to their radiological assessments, and tests that involve hematological and biochemical parameters as well as tumor markers that were performed before the initiation of the therapy. Response evaluation was carried out according to RE-CIST V1.1 response criteria at every 4th cycle of the chemotherapy. Hematological and biochemical parameters were repeated before every cycle of the chemotherapy.
All patients received bevacizumab 5 mg/kg IV (day 1) combined with irinotecan 180 mg/m 2 IV (day 1), leucovorin (LV) 200 mg/m 2 IV (day 1) and 5-fluorouracil (FU) (400 mg/m 2 IV bolus and then 2600 mg/m 2 continuous infusion for 46 hours) IV once every 2 weeks for 12 cycles. Eligible patients were those completing the whole course without the occurrence of grade 3 or 4 toxicity or tumor progression.
The control group consisted of 21 healthy volunteers, whose serum samples were collected in sterile test tubes, centrifuged at 3000 g for 10 min, and then stored at -80 0 C. 8 Serum VEGF concentrations between 40 and 600 pg/ml were reported by the manufacturer. The serum VEGF level of the control group was established to be 85.26 pg/ml (median 93.60 pg/ ml). The upper limit (mean control + 1standart deviation [SD]) was calculated to be 147.79 pg/ml. Serum bFGF concentrations were determined by a quantitative sandwich enzyme immunoassay technique (Invitrogen Immunoassay Kit). The serum bFGF level of the control group was 32.85 pg/ml (median 33.5 pg/ml). The upper limit (mean control + 1 SD) was calculated to be 37.74 pg/ml.
Statistical Analysis
Statistical analyzes were carried out by using the SPSS 12.0 for Windows software. Overall survival was calculated by using Kaplan-Meier method, and log-rank test was used for the differences between the survival curves. The Mann-Whitney U and Chi-square tests were used to compare the values in different groups for continuous variables and for categorical variables respectively. Prognostic factors were tested by Cox regression model. We utilized Pearson's correlation coefficient to evaluate the correlations between VEGF and bFGF, and the clinical parameters. The pre and post-treatment values were compared by using the paired samples t test. In all statistical analyzes p value, less than 0.05 was considered significant.
RESULTS
A total of 33 metastatic colorectal cancer patients receiving bevacizumab combined with chemotherapy were enrolled into the study. The median age of the patients was 61 years (38-75). Out of the 33 patients, 23 were females (69.7%). Characteristics of patients are summarized in Table 1 . The patients received 12 courses of FOLFIRI-bevacizumab therapy or until the disease progressed.
The response rates included partial response being 33.3%, stable disease being 36.3%, and progressive disease being 30.3%. The patients with progressive disease continued to receive treatment of chemotherapy (CT) schemas which was not delivered previously.
The mean of VEGF parameters of the control group was 85.26 ± 62.53 pg/ml while the median was 93.60 pg/ml, and the upper limit value was calculated 147.79 pg/ml with addition of mean + standard deviation. The mean of bFGF parameters of the control group was 32.85 ± 4.89 pg/ml while International Journal of Hematology and Oncology the median was 33.5 pg/ml, and the upper limit value was calculated to 37.74 pg/ml with addition of mean + standard deviation . The mean was 245.39 pg/ml and the median was 171 pg/ml for VEGF whereas the mean was 43.70 pg/ml and the median was 43.90 pg/ml for bFGF. The serum levels of VEGF and bFGF were significantly higher in the patient group than those of the control group (p< 0.001 vs. p< 0.001). Out of the 33 patients, 20 died (60.6%) during followup period. Mean overall survival of our patients were 13.53 months and mean progression-free survival of our patients was 23.97 months. (Figure 1 and Figure 2 )
Features of the patients were evaluated by the univariate analysis for progression-free survival (PFS), and bFGF (p= 0.026) was found to be a significant factor on PFS. As to overall survival. VEGF parameters of the patients were compared according to their condition under chemotherapy (partial response, stable disease or progressive disease). VEGF parameters of 11 patients with partial response under chemotherapy were compared to VEGF parameters prior to chemotherapy, and statistically significant differences were found (p< 0.01). In a partial response case, VEGF parameters of 12 patients with a stable response demonstrated significant differences in comparison to initial parameters (p< 0.05). There were statistically significant differences between the VEGF parameters and initial VEGF parameters of ten patients progressing under chemotherapy (p< 0.05). There was a statistically strong positive correlation between the initial and final (12th month) VEGF parameters of patients with partial response (r= 0.820; p< 0.01). No correlation was found between the initial and final VEGF parameters of the patients with a stable response and progressive course. There were International Journal of Hematology and Oncology no statistically significant differences between the initial and final bFGF parameters for the groups defined by clinical follow-up outcomes of the patients. There was a statistically positive correlation between the initial and final bFGF parameters of the patients with partial response (r= 0.687; p< 0.05). No correlation was found between the initial and final bFGF parameters of the patients with a stable response and progressive course. Table 2 presents the comparison results.
Serum VEGF level was not found a significant factor for the patients with rectum and colon cancer in progression free survival whereas sVEGF level was a significant factor for the patients with rectum cancer to determine overall survival. 
DISCUSSION
Colorectal carcinomas are globally one of the primary causes of mortality of cancer. Approximately 50% of the patients have relapse despite undergoing a curative surgery and die of metastatic disease. 9 We investigated the prognostic significance of VEGF and bFGF serum levels, which are important factors of angiogenesis, in colorectal cancer; their value to determine the response to treatment; and whether they were useful to identify the suitable group of patients for bevacizumab therapy in 33 patients diagnosed with metastatic colorectal cancer presented at our clinic.
In 1971, Judah Folkman first proposed that tumor angiogenesis could serve as a potential target for anticancer therapy. 10 In their study Nakayama et al. 11 found that the elevated plasma VEGF levels indicated recurrence and poor prognosis. Bevacizumab, the first FDA, approved the angiogenesis inhibitor humanized monoclonal Ig G antibody, inhibits VEGF. 12 The addition of bevacizumab to fluoropyrimidine-based chemotherapy, with or without irinotecan or oxaliplatin, in both the firstand second-line treatment of metastatic colorectal cancer, significantly increased median progression-free survival (PFS) and overall survival in select randomized phase III studies. 13 Out of the 33 patients in our study, 28 (84.4%) had undergone a surgery; 18 (54.5%) had tumor colon and 15 (45.5%) had rectum localized. The patients in our study had FOLFIRI/ bevacizumab, and the median International Journal of Hematology and Oncology PFS was 12.6 months, whereas the median overall survival was 24.3 months.
Hurwitz et al., conducted a study of 813 patients with mCRC and reported that the median survival increased from 15.6 months to 20.3 months (p< 0.001) with addition of bevacizumab to irinotecan, bolus 5-fluorouracil, and leucovorin (IFL); PFS increased from 6.2 months to 10.6 months; response rate raised from 34.8% to 44.8%, and the median duration of response increased from 7.1 months to 10.4 months in the first-line treatment.
14 Later, Hurwitz et al. conducted a Phase III study of 923 patients and compared 5-fluorouracil (5-FU)/ leucovorin (LV)/ bevacizumab or IFL/ bevacizumab to IFL/placebo in the first-line treatment. Although the overall survival was increased by 18.3 months in the 5-FU/LV /bevacizumab group and 15.1 months in the IFL/placebo group, this was not statistically significant. 15 In a study by Kabbinavar et al., 241 patients received 5-FU/LV or IFL, and 249 patients received 5-FU/LV/ bevacizumab. The overall survival was respectively 17.9 months, and 14.6 months whereas PFS was 8.8 months and 5.6 months in the 5-FU/LV/ bevacizumab group and the control group. 6 In the second-line setting bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) versus FOLFOX-4 for previously treated with mCRC patients was evaluated in ECOG 3200 a phase III randomized study. The bevacizumab arm was found to be associated with a superior response rate (21.8% versus 9.2%), median PFS (7.2 versus 4.8 months), and median OS (12.9 versus 10.8 months). 16 Broll et al. 17 indicated a significant correlation between the tumor volume and VEGF serum concentration in their study. They found that increased tumor mass was associated with high serum VEGF levels. Dirix et al. measured VEGF and bFGF in the sera of cancer patients and reported a strong correlation between the serum levels and tumor progression of both of the angiogenic factors. 18 Although Landriscina et al. found in their study that VEGF level in serum and tumor was correlated with the stage of the disease, the same correlation was not identified in bFGF. 19 In our study, bFGF significantly decreased in the patients with partial response during serum bFGF follow-up (p= 0.02) and increased in patients with a progressive course (p= 0.052).
SerumVEGF was significantly higher in our patient group (median 171 pg/ml and the mean 245.39 pg/ ml) than the control group. We compared the initial parameters with final parameters of VEGF by the responses under chemotherapy (partial response, stable response, progressive response) and found a significant decrease in the parameters. A strong positive correlation was found between the initial and final parameters of VEGF only in the patients with partial response.
In the individual analyses conducted for colon and rectum cancer, the patients with rectum cancer who had normal serum levels of VEGF in the beginning of the treatment had significantly longer overall survival than those with higher VEGF (27.93 months vs. 23.37 months) (p= 0.026). The patients with colon cancer, who had normal serum VEGF levels prior to the treatment, lived longer, but this was statistically insignificant. Unlike those with colon cancer, the initial sVEGF level was a significant indicator for overall survival of the patients with rectum cancer in our patients. Furthermore, the patients with partial response initially had a higher sVEGF level, and the PFS was increased by antiVEGF treatment.
It will be more accurate to define carcinogenesis according to molecular characteristics of the tumor and host rather than the stage of the disease. The treatment should be planned not only by tumor localization but also by the molecular biology of the tumor and individual. 20 When biomarkers are widely and clinically used, they will be helpful with noninvasive treatment planning. 21 With antiVEGF treatment, the PFS was higher in our patients who initially had high serum VEGF levels. However, this was statistically significant with shorter survival in rectum cancer. In the beginning of this treatment, the overall survival of those with high sVEGF was short but the PFS was longer, which suggests that a greater response to bevacizumab therapy in those with high sVEGF levels could be achieved.
The adverse effects that might occur with the addition of bevacizumab to chemotherapy were International Journal of Hematology and Oncology reported to be GI perforation, complications of hemorrhage, arterial thromboembolism, hypertension, proteinuria, and epistaxis. 22 We fortnightly administered 5 mg/kg dose of bevacizumab to the patients. The FOLFIRI /bevacizumab combination regimen was well tolerated by the patients. None of our patients died due to the treatment.
In conclusion, serum VEGF is indicative for PFS and overall survival in patients with mCRC. Based on limited numeral parameters, we also found in our study that serum bFGF levels might be useful to determine the response to the treatment during the course of treatment. The response rate of the patients who initially had higher serum VEGF levels to the antiangiogenic therapy found to be high. This finding suggests that the determination of initial sVEGF levels may be useful to select the patients with mCRC to receive bevacizumab therapy; however this should be supported by further prospective studies.
